Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 32.50 | 0.36% |
| CAC 40 | 8,061.13 | 110.95 | 1.40% |
| DAX 40 | 23,983.60 | 413.64 | 1.75% |
| Dow JONES (US) | 47,306.83 | 319.73 | 0.68% |
| FTSE 100 | 9,781.02 | 98.45 | 1.02% |
| HKSE | 26,649.06 | 163.16 | 0.62% |
| NASDAQ | 23,422.98 | 418.44 | 1.82% |
| Nikkei 225 | 50,911.76 | 28.08 | 0.06% |
| NZX 50 Index | 13,617.48 | 40.67 | 0.30% |
| S&P 500 | 6,807.06 | 78.26 | 1.16% |
| S&P/ASX 200 | 8,835.90 | 25.40 | 0.29% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |